LA JOLLA, Calif., Oct. 30, 2024 /PRNewswire/ — CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical firm targeted on creating novel calcium release-activated calcium (“CRAC”) channel inhibition therapies for acute and continual inflammatory and immunologic sicknesses, as we speak introduced the pricing of an underwritten public providing of two,720,000 shares of its widespread inventory at a price to the general public of $3.75 per share. The gross proceeds to the Firm from the providing, earlier than deducting underwriting reductions and commissions and providing bills, are anticipated to be $10,200,000. As well as, the Firm has granted the underwriters a 30-day choice to buy up to an extra 408,000 shares of its widespread inventory on the public providing price, much less underwriting reductions and commissions. The entire shares are to be offered by the Firm. The providing is predicted to shut on or about November 1, 2024, topic to satisfaction of customary closing circumstances.

Jones is appearing as the only book-running supervisor for the providing.

The underwritten public providing is being made pursuant to a shelf registration assertion on Type S-3 (File No. 333-273949) (together with a base prospectus) beforehand filed with the Securities and Trade Fee (the “SEC“) on August 11, 2023 and declared efficient by the SEC on August 18, 2023. A preliminary prospectus complement and the accompanying prospectus referring to and describing the phrases of the underwritten public providing had been filed with the SEC on October 30, 2024. A last prospectus complement referring to the providing will probably be filed with the SEC and will probably be accessible on the SEC’s web site at www.sec.gov. When accessible, digital copies of the ultimate prospectus complement and the accompanying prospectus referring to the underwritten public providing can also be obtained by contacting: JonesTrading Institutional Providers LLC, Consideration: Fairness Capital Markets, 325 Hudson (NYSE:) Road, sixth Ground New York, New York 10013; e mail: ecm@jonestrading.com.

This press release doesn’t represent a proposal to promote or the solicitation of a proposal to purchase, nor shall there be any sale of those securities in any state or jurisdiction by which such supply, solicitation or sale could be illegal previous to the registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical firm targeted on creating novel CRAC channel inhibition therapies for inflammatory and immunologic ailments. CalciMedica’s proprietary know-how targets the inhibition of CRAC channels to modulate the immune response and defend towards tissue cell harm, with the potential to offer therapeutic advantages in life-threatening inflammatory and immunologic ailments for which there are presently no permitted therapies. CalciMedica’s lead product candidate Auxora™ has demonstrated optimistic and constant scientific leads to a number of accomplished efficacy scientific trials. CalciMedica has introduced knowledge for a Section 2b trial (referred to as CARPO “ NCT04681066) in sufferers with AP with SIRS and accomplished a Section 2 trial (referred to as CARDEA “ NCT04345614) in sufferers with COVID pneumonia. The Firm is presently conducting a Section 2 trial (referred to as KOURAGE “ NCT06374797) in sufferers with AKI with related AHRF with knowledge anticipated in 2025 and persevering with to assist the continued Section 1/2 trial (referred to as CRSPA “ NCT04195347) in sufferers with AIPT with knowledge anticipated in 2025. CalciMedica was based by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Analysis, and is headquartered in La Jolla, CA.

Ahead-Trying Statements
Any statements on this press release about future expectations, plans and prospects for CalciMedica, together with statements concerning the timing and completion of the underwritten public providing, and different statements containing the phrases “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and related expressions, represent forward-looking statements inside the that means of The Personal Securities Litigation Reform Act of 1995. Precise outcomes could differ materially from these indicated by such forward-looking statements because of varied vital components, together with: CalciMedica’s incapacity, or the shortcoming of the underwriter, to fulfill the circumstances to closing for the underwritten public providing; and financial, enterprise, aggressive, and/or regulatory components affecting the enterprise of CalciMedica typically. Extra dangers and uncertainties that might trigger precise outcomes and outcomes to vary materially from these contemplated by the forward-looking statements are included beneath the caption “Risk Factors” in CalciMedica’s Quarterly Report on Type 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024 and different filings CalciMedica makes with the SEC now and again and accessible at www.sec.gov. All forward-looking statements contained on this press release converse solely as of the date on which they had been made. CalciMedica undertakes no obligation to replace such statements to replicate occasions that happen or circumstances that exist after the date on which they had been made, besides as required by regulation.

CalciMedica Contact:
Buyers and Media
Argot CompanionsSarah Sutton/Kevin Murphycalcimedica@argotpartners.com
(212) 600-1902